The University of Southampton
University of Southampton Institutional Repository

Risk of fracture with thiazolidinediones: disease or drugs?

Risk of fracture with thiazolidinediones: disease or drugs?
Risk of fracture with thiazolidinediones: disease or drugs?
The use of thiazolidinediones (TZDs) has been associated with an increased fracture risk. In addition, type 2 diabetes mellitus (T2DM) has been linked with fracture. We evaluated to what extent the association between TZD use and fracture risk is related to the drug or to the underlying disease. We conducted a population-based cohort study using the Danish National Health Registers (1996–2007), which link pharmacy data to the national hospital registry. Oral antidiabetic users (n = 180,049) were matched 1:3 by year of birth and sex to nonusers. Cox proportional hazards models were used to estimate hazard ratios (HRs) of fracture. Time-dependent adjustments were made for age, comorbidity, and drug use. We created a proxy indicator for the severity of disease. The first stage was defined as current use of either a biguanide or a sulfonyluerum, the second stage as current use of a biguanide and a sulfonyluerum at the same time, the third stage as patients using TZDs, and the fourth stage as patients using insulin. The risk of osteoporotic fracture was increased 1.3-fold for stages 3 and 4 compared with controls. Risk with current TZD use (stage 3 HR = 1.27, 95% CI 1.06–1.52) and risk with current use of insulin (stage 4 HR = 1.25, 95% CI 1.20–1.31) were similar. In the first (HR = 1.15, 95% CI 1.13–1.18) and second (HR = 1.00, 95% CI 0.96–1.04) stages risks were lower. Risk of osteoporotic fracture was similar for TZD users and insulin users. When studying fracture risk with TZDs, the underlying T2DM should be taken into account.
thiazolidinedione, type 2 diabetes mellitus, fracture risk, osteoporosis
0171-967X
450-457
Bazelier, Marloes T.
701385a8-2cb1-4258-88a4-249c3a7f07f5
Vestergaard, Peter
3336d4f1-072c-4b02-935e-a5eca05858e2
Gallagher, Arlene M.
4a77b2c1-c628-47e0-a29c-f726ca3445bc
van Staa, Tjeerd-Pieter
f840d545-0e8d-40fe-9124-976826190cc3
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Leufkens, Hubert G. M.
3c6f2841-6825-4de0-b967-1d4aa5498a5d
de Vries, Frank
10245a32-6083-4feb-9d20-7e7db0f358b1
Bazelier, Marloes T.
701385a8-2cb1-4258-88a4-249c3a7f07f5
Vestergaard, Peter
3336d4f1-072c-4b02-935e-a5eca05858e2
Gallagher, Arlene M.
4a77b2c1-c628-47e0-a29c-f726ca3445bc
van Staa, Tjeerd-Pieter
f840d545-0e8d-40fe-9124-976826190cc3
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Leufkens, Hubert G. M.
3c6f2841-6825-4de0-b967-1d4aa5498a5d
de Vries, Frank
10245a32-6083-4feb-9d20-7e7db0f358b1

Bazelier, Marloes T., Vestergaard, Peter, Gallagher, Arlene M., van Staa, Tjeerd-Pieter, Cooper, Cyrus, Leufkens, Hubert G. M. and de Vries, Frank (2012) Risk of fracture with thiazolidinediones: disease or drugs? Calcified Tissue International, 90 (6), 450-457. (doi:10.1007/s00223-012-9591-8). (PMID:22488176)

Record type: Article

Abstract

The use of thiazolidinediones (TZDs) has been associated with an increased fracture risk. In addition, type 2 diabetes mellitus (T2DM) has been linked with fracture. We evaluated to what extent the association between TZD use and fracture risk is related to the drug or to the underlying disease. We conducted a population-based cohort study using the Danish National Health Registers (1996–2007), which link pharmacy data to the national hospital registry. Oral antidiabetic users (n = 180,049) were matched 1:3 by year of birth and sex to nonusers. Cox proportional hazards models were used to estimate hazard ratios (HRs) of fracture. Time-dependent adjustments were made for age, comorbidity, and drug use. We created a proxy indicator for the severity of disease. The first stage was defined as current use of either a biguanide or a sulfonyluerum, the second stage as current use of a biguanide and a sulfonyluerum at the same time, the third stage as patients using TZDs, and the fourth stage as patients using insulin. The risk of osteoporotic fracture was increased 1.3-fold for stages 3 and 4 compared with controls. Risk with current TZD use (stage 3 HR = 1.27, 95% CI 1.06–1.52) and risk with current use of insulin (stage 4 HR = 1.25, 95% CI 1.20–1.31) were similar. In the first (HR = 1.15, 95% CI 1.13–1.18) and second (HR = 1.00, 95% CI 0.96–1.04) stages risks were lower. Risk of osteoporotic fracture was similar for TZD users and insulin users. When studying fracture risk with TZDs, the underlying T2DM should be taken into account.

This record has no associated files available for download.

More information

Published date: June 2012
Keywords: thiazolidinedione, type 2 diabetes mellitus, fracture risk, osteoporosis
Organisations: Faculty of Health Sciences

Identifiers

Local EPrints ID: 339042
URI: http://eprints.soton.ac.uk/id/eprint/339042
ISSN: 0171-967X
PURE UUID: 65cfdaf9-8150-494b-b484-6610909a8514
ORCID for Cyrus Cooper: ORCID iD orcid.org/0000-0003-3510-0709

Catalogue record

Date deposited: 22 May 2012 11:19
Last modified: 18 Mar 2024 02:45

Export record

Altmetrics

Contributors

Author: Marloes T. Bazelier
Author: Peter Vestergaard
Author: Arlene M. Gallagher
Author: Tjeerd-Pieter van Staa
Author: Cyrus Cooper ORCID iD
Author: Hubert G. M. Leufkens
Author: Frank de Vries

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×